Patrys Advances RLS-2202 Phase 1A Trial Setup with Q3 2026 Dosing Goal Following A$3.1M Capital Raise

RLS-2202 Regulatory Strategy and Clinical Development Plan

RLS-2202 is Patrys' lead clinical asset, a proprietary injectable quetiapine formulation targeting delirium treatment in acute care. The company is pursuing the FDA 505(b)(2) regulatory pathway, leveraging existing quetiapine safety and clinical data while generating new data specific to its injectable form. This approach aims to streamline development by building on the known safety profile of quetiapine while demonstrating the novel formulation's benefits.

The Phase 1A bridging study in healthy volunteers is a critical early milestone designed to evaluate safety, tolerability, and pharmacokinetics of RLS-2202. This study will generate formulation-specific data in healthy subjects before advancing to patient populations, supporting progression to later-stage clinical trials in delirium patients.

Clinical Trial Infrastructure Established with CMAX and Alithia Life Sciences

During the June quarter, Patrys completed a competitive selection process, appointing CMAX as the Phase 1A clinical trial site and Alithia Life Sciences as the CRO. CMAX will manage participant dosing and monitoring, utilizing its specialized Phase 1 facilities, experienced investigators, and recruitment capabilities. This selection ensures access to necessary infrastructure and expertise for early human studies.

Alithia Life Sciences will oversee operational, regulatory, and clinical management, including project management, regulatory coordination, data handling, pharmacovigilance, vendor oversight, biostatistics, and reporting. These appointments create a comprehensive operational framework for the Phase 1A trial, reflecting both organizations' extensive early-stage clinical development experience.

Progress on Phase 1A Study and HREC Submission

Significant progress was made in Phase 1A study planning during the June quarter, with protocol finalization and submission of the Human Research Ethics Committee application. The finalized protocol details methodology, safety measures, participant criteria, and data collection, aligning with regulatory requirements.

Drug product for cohort 1 has been manufactured and awaits release, indicating parallel progress in manufacturing and regulatory activities. Preparations at CMAX for participant enrollment are underway. Subject to HREC approval, Therapeutic Goods Administration Complaint Therapeutic Note notification, site governance approval, and registration with the Australian and New Zealand Clinical Trials Registry, first participant dosing remains targeted for Q3 2026.

A$3.1 Million Capital Raise Fuels Clinical Advancement

Patrys successfully raised approximately A$3.1 million (before costs) in the June quarter via the issue of around 131 million fully paid ordinary shares at A$0.024 each. Following shareholder approval at the 8 June 2026 General Meeting, placement participants received one free attaching unlisted option per four shares subscribed, exercisable at A$0.048 until 30 November 2030. This structure aligns shareholder interests with the company's clinical and regulatory milestones.

Company directors participated on identical terms, investing an additional A$210,000, underscoring management's confidence. Funds will support Phase 1A trial execution, manufacturing, regulatory activities, IP portfolio advancement, and working capital. The placement reflects strong investor support and strengthens the balance sheet for RLS-2202’s early-stage clinical development.

Cash Position and Operating Expenses in June Quarter

Patrys closed the quarter with A$3.36 million in cash following the capital raise and operational expenditures. Net operating cash outflows totaled A$789,000, primarily funding RLS-2202 manufacturing, regulatory, and clinical planning activities. The company also invested in intellectual property protection for RLS-2202 and deoxymab programs.

Payments to related parties amounted to A$74,610, covering Non-Executive Director fees as disclosed in Appendix 4C Section 6. The burn rate reflects the company’s development stage and investment in advancing Phase 1A trial readiness. Cash position and burn rate are key metrics for investors assessing operational runway.

Deoxymab Platform and Post-Quarter Development Agreement

In addition to RLS-2202, Patrys is developing the deoxymab platform targeting immune-mediated inflammatory diseases. The company supports ongoing preclinical research collaborations, including vasculitis studies involving DX1 and DX3 compounds, managing capital requirements while maintaining program involvement.

After the June quarter, Patrys entered a binding agreement to advance and commercialize its deoxymab IP portfolio, retaining 50% of future commercialization revenue while significantly reducing capital needs. This arrangement transfers development and commercialization responsibilities while preserving economic interest. Further details were provided in a 13 July 2026 company announcement.

Clinical-Stage Positioning and Development Outlook

Patrys is a clinical-stage company with RLS-2202 as its lead asset progressing toward human trials. Having completed preclinical work, the company is advancing into Phase 1 clinical evaluation in healthy volunteers, marking a significant step in drug development. This phase involves increased costs and timelines due to regulatory requirements for safety and efficacy data.

The company’s dual-platform strategy, advancing RLS-2202 while maintaining exposure to deoxymab via the post-quarter agreement, provides portfolio diversification. This approach supports progression through Phase 1A studies, potential Phase 2 trials, and eventual regulatory submissions.

Investor Insights and Development Timeline

Investors should focus on the upcoming milestone of first participant dosing in the RLS-2202 Phase 1A study, targeted for Q3 2026 pending regulatory approvals. This milestone will initiate human safety and pharmacokinetic data generation. Delays in HREC approval, TGA CTN notification, site governance, or trial registration could impact this timeline.

The June quarter capital raise and A$3.36 million cash balance, combined with a quarterly burn rate of A$789,000, provide operational runway for several quarters at current spending levels. The deoxymab agreement further reduces capital demands, potentially extending financial runway. Investors should monitor cash updates, regulatory progress, and trial outcomes closely.

Regulatory and Clinical Trial Risks

Patrys must secure multiple regulatory approvals before commencing Phase 1A dosing, including HREC approval, TGA CTN notification, site governance clearance, and ANZCTR registration. Delays or required protocol modifications could postpone dosing beyond Q3 2026. Changes in regulatory or ethical review policies may also affect timelines or study design.

Clinical risks include potential unexpected safety, tolerability, or pharmacokinetic issues during human testing that were not evident preclinically. Such findings could necessitate dosing adjustments, additional studies, or raise concerns about the formulation’s viability. Recruitment and retention challenges could also affect study timelines and data completeness. Investors should weigh these risks when evaluating Patrys’ development program.